Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa K Naeger

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
AIDS (London, England)|January 2, 2007
Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patientsLisa K Naeger, Kimberly A Struble
AIDS (London, England)|March 22, 2006
Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patientsLisa K Naeger, Kimberly A Struble
Hepatology (Baltimore, Md.)|November 19, 2011
Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatmentPatrick R Harrington, Wen Zeng, Lisa K Naeger
Hepatology (Baltimore, Md.)|July 19, 2012
Reply: To PMID 22095516Patrick R Harrington, Lisa K Naeger, Wen Zeng
Antiviral Therapy|February 12, 2016
Effect of dolutegravir functional monotherapy on HIV-1 virological response in integrase strand transfer inhibitor resistant patientsLisa K Naeger, Patrick Harrington, Takashi Komatsu, et al.
Antimicrobial Agents and Chemotherapy|June 19, 2002
ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptaseLisa K Naeger, Nicolas A Margot, Michael D Miller
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 11, 2019
Hepatitis C Virus RNA Levels Following Virologic Failure With Direct-acting Antivirals: Implications for Lower Sensitivity Diagnostic AssaysPatrick R Harrington, Takashi E Komatsu, Hengrui Sun, et al.
Antiviral Research|November 5, 2013
Resistance of human cytomegalovirus to ganciclovir/valganciclovir: a comprehensive review of putative resistance pathwaysTakashi E Komatsu, Andreas Pikis, Lisa K Naeger, et al.
Hepatology (Baltimore, Md.)|October 24, 2017
Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluationKimberly Struble, Kirk Chan-Tack, Karen Qi, et al.
Hepatology (Baltimore, Md.)|August 16, 2014
Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvirEric F Donaldson, Patrick R Harrington, Julian J O'Rear, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
AIDS (London, England)|January 2, 2007
Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patientsLisa K Naeger, Kimberly A Struble
AIDS (London, England)|March 22, 2006
Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patientsLisa K Naeger, Kimberly A Struble
Hepatology (Baltimore, Md.)|November 19, 2011
Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatmentPatrick R Harrington, Wen Zeng, Lisa K Naeger
Hepatology (Baltimore, Md.)|July 19, 2012
Reply: To PMID 22095516Patrick R Harrington, Lisa K Naeger, Wen Zeng
Antiviral Therapy|February 12, 2016
Effect of dolutegravir functional monotherapy on HIV-1 virological response in integrase strand transfer inhibitor resistant patientsLisa K Naeger, Patrick Harrington, Takashi Komatsu, et al.
Antimicrobial Agents and Chemotherapy|June 19, 2002
ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptaseLisa K Naeger, Nicolas A Margot, Michael D Miller
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 11, 2019
Hepatitis C Virus RNA Levels Following Virologic Failure With Direct-acting Antivirals: Implications for Lower Sensitivity Diagnostic AssaysPatrick R Harrington, Takashi E Komatsu, Hengrui Sun, et al.
Antiviral Research|November 5, 2013
Resistance of human cytomegalovirus to ganciclovir/valganciclovir: a comprehensive review of putative resistance pathwaysTakashi E Komatsu, Andreas Pikis, Lisa K Naeger, et al.
Hepatology (Baltimore, Md.)|October 24, 2017
Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluationKimberly Struble, Kirk Chan-Tack, Karen Qi, et al.
Hepatology (Baltimore, Md.)|August 16, 2014
Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvirEric F Donaldson, Patrick R Harrington, Julian J O'Rear, et al.
Pageof 3